500 related articles for article (PubMed ID: 22160057)
1. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
2. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
3. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
4. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
5. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic dysregulation of leukaemic HOX code in MLL-rearranged leukaemia mouse model.
Ng RK; Kong CT; So CC; Lui WC; Chan YF; Leung KC; So KC; Tsang HM; Chan LC; Sham MH
J Pathol; 2014 Jan; 232(1):65-74. PubMed ID: 24122813
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
9. In focus: MLL-rearranged leukemia.
de Boer J; Walf-Vorderwülbecke V; Williams O
Leukemia; 2013 Jun; 27(6):1224-8. PubMed ID: 23515098
[TBL] [Abstract][Full Text] [Related]
10. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
Juszczynski P; Rodig SJ; Ouyang J; O'Donnell E; Takeyama K; Mlynarski W; Mycko K; Szczepanski T; Gaworczyk A; Krivtsov A; Faber J; Sinha AU; Rabinovich GA; Armstrong SA; Kutok JL; Shipp MA
Clin Cancer Res; 2010 Apr; 16(7):2122-30. PubMed ID: 20332322
[TBL] [Abstract][Full Text] [Related]
11. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.
Dorrance AM; Liu S; Yuan W; Becknell B; Arnoczky KJ; Guimond M; Strout MP; Feng L; Nakamura T; Yu L; Rush LJ; Weinstein M; Leone G; Wu L; Ferketich A; Whitman SP; Marcucci G; Caligiuri MA
J Clin Invest; 2006 Oct; 116(10):2707-16. PubMed ID: 16981007
[TBL] [Abstract][Full Text] [Related]
12. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
14. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
[TBL] [Abstract][Full Text] [Related]
15. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
16. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
17. A role for DOT1L in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Epigenomics; 2011 Dec; 3(6):667-70. PubMed ID: 22126283
[No Abstract] [Full Text] [Related]
18. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
19. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
20. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]